<DOC>
	<DOCNO>NCT00982254</DOCNO>
	<brief_summary>This study compare pharmacokinetic pharmacodynamic property oral insulin formulation standard subcutaneous injection regular human insulin .</brief_summary>
	<brief_title>Oral Insulin : A Comparison With Subcutaneous Regular Human Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This study single centre , randomize , 3-period crossover study perform patient type 2 diabetes . Patients receive single dos oral insulin formulation subcutaneous regular human insulin separate visit . The primary objective study compare pharmacokinetic pharmacodynamic property oral insulin formulation 15 U subcutaneous inject regular human insulin . Pharmacokinetic pharmacodynamic parameter include bioavailability bioefficacy measure 6-hour glucose clamp experiment . Study duration : 2 month</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male subject age 35 70 year , inclusive , Type 2 diabetes mellitus define ADA criterion one year Subjects must Body Mass Index ( BMI ) &lt; 36 kg/m² Stable glycemic control ( HbA1C &lt; 11 % ) Subjects must oral hypoglycemic agent 24 hour prior study dose day investigational drug least 4 week Subjects must refrain strenuous physical activity begin 72 hour prior admission duration study Subjects must willing able confine Clinical Research Unit require protocol Subjects must willing able provide write informed consent History presence clinically significant cardiovascular , respiratory , hepatic , renal , gastrointestinal , neurological infectious disorder capable alter absorption , metabolism elimination drug , constitute risk factor take study medication Subjects gastroparesis , orthostatic hypotension hypoglycemia unawareness ( autonomic neuropathy ) . Subjects `` brittle '' diabetes predisposition severe hypoglycemia , e.g. , 2 serious hypoglycemic episode ( require another 's assistance ) within past year , hospitalization emergency room visit due poor diabetic control within past 6 month . Evidence significant active hematological disease and/or cumulative blood donation 1 unit ( 500 mL ) include blood drawn clinical trial last 3 month Positive hepatitis B ( hepatitis B surface antigen ) and/or hepatitis C ( hepatitis C antibody ) serology Positive HIV serology Evidence significant active neuropsychiatric disease Known allergy human insulin excipients contain product Regular alcohol intake great 28 units*/week ( male ) , 21 units/week ( female ) , subject unwilling stop alcohol duration study ( * 1 unit = 8 g ethanol , ¼ liter beer 1 glass wine 1 measure spirit ) Intake drug evaluation investigator may interfere interpretation trial result know cause clinically relevant interference insulin action , glucose utilisation recovery hypoglycaemia . Treatment s.c. insulin injection . Investigators , site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt Have condition ( include drug abuse , alcohol abuse , psychiatric disorder ) , opinion investigator , precludes patient follow complete protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Oral Insulin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>